- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00809185
RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes
A Phase 2 Trial of RAD001(Everolimus) in Low and Intermediate-1 Risk Myelodysplastic Syndrome
RATIONALE: RAD001(Everolimus) may stop the growth of cancer cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the cancer.
PURPOSE: This phase II trial is studying how well RAD001(everolimus) works in treating patients with myelodysplastic syndromes.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
OBJECTIVES:
Primary
- Determine the clinical activity (improvement in erythroid response and/or improvement in other cytopenias, bone marrow morphology/cytogenetics) of RAD001(everolimus) in patients with low or intermediate-1 risk myelodysplastic syndromes.
- Assess the toxicity of this drug in these patients.
Secondary
- Examine laboratory correlates (S6K1 levels, angiogenesis pre- and post-treatment) and determine how these correlates correspond to dosing and clinical activity of RAD001(everolimus).
- Evaluate the presence of HLA-DR15 and cytotoxic T-cell populations in patients pre- and post-treatment and correlate this with response to treatment.
- Examine the incidence of the null GSTT-1 phenotype in myelodysplastic syndromes patients and correlate this with response to RAD001(everolimus).
OUTLINE: Patients receive oral RAD001(everolimus) once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or relapse.
Blood samples are collected periodically during study. Samples are analyzed for S6K1 activity, effector T cells by flow cytometry, GSTT-1 by PCR, and HLA-DR15 levels.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
Low or intermediate-1 risk myelodysplastic syndromes by International Prognostic Scoring System (IPSS) criteria
- IPSS score < 1.5
- Requiring transfusion of 2 units of red blood cells at least once a month (four weeks prior to accrual on study)
High levels of endogenous epoetin alfa (i.e., > 200 mU/mL)
- Unlikely to respond to epoetin alfa, or has a documented clinical non-response to epoetin alfa (at a dose of ≥ 40,000 U weekly) or darbepoetin alfa (at a dose > 200 mcg every other week) (i.e., < 2 g/dL increase in hemoglobin and no decrease in transfusion requirements after at least 4 weeks of treatment)
- No chronic myelomonocytic leukemia
PATIENT CHARACTERISTICS:
- ECOG Performance Status of 0-2
- Liver enzymes (AST and ALT) and total bilirubin ≤ 2 times upper limit of normal
- Serum creatinine ≤ 2 times upper limits of normal
- No clinically significant anemia due to iron, B12, or folate deficiencies; autoimmune or hereditary hemolysis; or gastrointestinal bleeding
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other serious or poorly controlled medical condition that could be exacerbated by or complicate compliance with study therapy
PRIOR CONCURRENT THERAPY:
- At least 4 weeks since prior treatment (including growth factors)
- No chronic use (> 2 weeks) of physiologic doses of a corticosteroid agent (dose equivalent to > 10 mg/day of prednisone) within 28 days of the first day of study drug
- No concurrent use of another investigational agent
- No concurrent therapy with any cytotoxic drugs, steroids, or growth factors
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: RAD001 (everolimus)
RAD001 (everolimus) at 10mg/day with Bone marrow aspirate/biopsy and other laboratory biomarker analysis
|
Patients will receive monotherapy with RAD001(everolimus)for 21 days within the 28 day cycle.
Andre navn:
Laboratory correlates (cytotoxic t cell populations, S6K1 levels, GSTT-1 mutations, and the presence or absence of HLA-DR15) will be assessed to see if any of these correlates correspond to response.
Bone marrow aspirate and biopsy with cytogenetics should be obtained within 4 weeks prior to starting drug and at week 33.
A bone marrow aspirate and biopsy should also be obtained for patients going off study prior to week 33 (including cytogenetics).
The percentage of blasts on the aspirate should be used to determine the IPSS score.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of Patients With Either a Major or Minor Erythroid Response (Hemoglobin Change From Baseline Measure)
Tidsramme: 2 years of treatment
|
Major erythroid response: (1) For patients with a baseline hemoglobin less than 11 g/dL, a major erythroid response is defined as a > 2 g/dL increase in hemoglobin from baseline; or (2) 100% decrease in red blood cell transfusion requirements. Minor erythroid response: (1) For patients with baseline hemoglobin less than 11 g/dL, a minor erythroid response is defined as an increase in hemoglobin greater than 1 g/dL but less than 2 g/dL from baseline; or (2) > 50% decrease in red blood cell transfusion requirements. |
2 years of treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of Dose- and Non-dose-limiting Toxicities
Tidsramme: at end of one cycle (28 days)
|
Number of Dose- and Non-dose-limiting Toxicities at the end of cycle 1 associated with RAD001 (see AE/SAE section for details).
|
at end of one cycle (28 days)
|
Number of Participants With Bone Marrow Morphology and Cytogenetics Pre- and Post-therapy
Tidsramme: at 2 years of treatment
|
Number of Participants with change in bone marrow morphology and cytogenetics
|
at 2 years of treatment
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Laboratory Correlates (Cytotoxic T-cell Populations, S6K1 Levels, GSTT-1 Mutations, and Presence or Absence of HLA-DR15)
Tidsramme: at 2 years of treatment
|
T-cell populations in patients pre- and post-treatment
|
at 2 years of treatment
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studiestol: Anjali Advani, MD, Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CASE1905 (Annen identifikator: Case Comprehensive Cancer Center)
- P30CA043703 (U.S. NIH-stipend/kontrakt)
- CASE-CCF-8514 (Annen identifikator: Cleveland Clinic IRB)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Myelodysplastiske syndromer
-
M.D. Anderson Cancer CenterHar ikke rekruttert ennåMyeloproliferativ neoplasma | Myelodysplastisk neoplasma | Pathway Mutant Myelodysplastic SyndromeForente stater
-
University of Colorado, DenverRekrutteringKlinefelters syndrom | Trisomi X | XYY syndrom | XXXY og XXXXY syndrom | Xxyy syndrom | Xyyy syndrom | Xxxx syndrom | Xxxxx syndrom | Xxxyy syndrom | Xxyyy syndrom | Xyyyy syndrom | Mann med sexkromosommosaikkForente stater
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.FullførtTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapierelatert myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært høyrisiko myelodysplastisk syndromForente stater
-
University of NottinghamMedical Research Council; National Institute for Health Research, United...RekrutteringSkrøpelig eldre syndrom | Skrøpelighet | Skrøpelighet syndromStorbritannia
-
Assistance Publique - Hôpitaux de ParisRekrutteringIntensivavdelingens syndrom | Pediatrisk postintensiv syndromFrankrike
-
Hospital Universitario GetafeKarolinska Institutet; Medical University of Lodz; Universidad Politecnica... og andre samarbeidspartnereUkjentSkrøpelig eldre syndrom | Skrøpelighet | Skrøpelighet syndromPolen, Spania, Sverige
-
Shaare Zedek Medical CenterUkjentPremenstruelt syndrom - PMS
-
Brigham and Women's HospitalAktiv, ikke rekrutterendeSkrøpelig eldre syndrom | Skrøpelighet | Aldring | Skrøpelighet syndromForente stater
-
Hrain Biotechnology Co., Ltd.Shanghai Changzheng HospitalAktiv, ikke rekrutterendePOMES syndrom | Tilbakefallende og refraktær POMES-syndromKina
-
Esra ÖZERKTO Karatay UniversityRekrutteringPremenstruelt syndrom - PMSTyrkia
Kliniske studier på everolimus
-
Novartis PharmaceuticalsFullførtLymfangioleiomyomatose (LAM) | Tuberøs sklerosekompleks (TSC)Forente stater, Storbritannia, Tyskland, Italia, Den russiske føderasjonen, Nederland, Japan, Canada, Polen, Frankrike, Spania
-
Novartis PharmaceuticalsAvsluttetHepatocellulært karsinomHong Kong, Taiwan, Thailand
-
The Netherlands Cancer InstituteAktiv, ikke rekrutterendeNevroendokrine karsinomerNederland
-
German Breast GroupNovartisAvsluttetMetastatisk brystkreftTyskland
-
University of LuebeckAvsluttetKoronararteriesykdomTyskland
-
Novartis PharmaceuticalsFullførtGastroenteropankreatisk nevroendokrin svulst i lunge- eller gastroenteropankreatisk systemTyskland
-
Guangdong Provincial People's HospitalNovartisUkjentNevroendokrine svulster | Karsinoid svulstKina
-
Asan Medical CenterFullførtNeoplasma i magenKorea, Republikken
-
Leiden University Medical CenterUkjentHode- og nakkekreftNederland
-
Novartis PharmaceuticalsAvsluttetKarsinom, nyrecelleAustralia, Korea, Republikken